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Aim: Develop a platform composed of labeled dendrimer nanoparticles (NPs) and a 
microfluidic device for real-time monitoring of cancer cells fate. Materials & methods: 
Carboxymethylchitosan/poly(amidoamine) dendrimer NPs were labeled with 
fluorescein-5(6)-isothiocyanate and characterized using different physicochemical 
techniques. After, HeLa, HCT-116 and U87MG were cultured in the presence of NPs, 
and cell viability and internalization efficiency in static (standard culture) and dynamic 
(microfluidic culture) conditions were investigated. Results: Cancer cells cultured with 
NPs in dynamic conditions were viable and presented higher internalization levels 
as compared with static 2D cultures. Conclusion: This work demonstrated that the 
proposed microfluidic-based platform allows real-time monitoring, which upon more 
studies, namely, the assessment of an anticancer drug release effect could be used for 
cancer theranostics.
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Published online: 10 February 2017
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Cancer is a major cause of mortality, being 
directly responsible for 1,665,540 new can-
cer cases and 585,720 cancer deaths in the 
USA in 2014 [1]. Its incidence is estimated 
to increase up to 13 million by 2030, world-
wide [2]. The metastasis process, where circu-
lating tumor cells (CTCs) migrate and colo-
nize distant organs, is responsible for about 
90% of deaths [3]. Thus, CTCs have been 
highly studied, and new information has 
arisen regarding its fate and subsequent host 
interaction, the importance of shear stress 
and real-time visualization in understanding 
these processes [4]. New strategies for cancer 
diagnosis and treatment have become more 
sophisticated and high-throughput processes 
have been applied due to forward-thinking 
nanotechnology techniques, such as the use 
of nanoparticles (NPs). In fact, NP can be 
modified to target-specific cells, as CTCs, 
and induce specific cancer cell death [5]. Addi-
tionally, these nanometer-sized structures 
are very attractive for health-related appli-
cations, as they can be rationally designed 
taking advantage of the cut-off pore size of 
the vasculature, in other words, enhanced 
permeation and retention effect, allowing 
these to be used for imaging, diagnosis and 
therapy, holding great promise in the cancer 
field [6,7]. The possibility of being designed 
on demand is one of the major advantages of 
such nanotools. In this reasoning, they can 
be used both in the preparation of cell-track-
ing tools (such as migration patterns and 
response to physical and chemical factors) 
and the visualization of delivery and distri-
bution of drugs in real time [8]. Recently, 
imaging tools such as microscopy images 
obtained in static 2D conditions have been 
used to determine abnormal cellular distri-
bution patterns [9], which could indicate loss 
of adherence, a crucial step for cancer pro-
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gression. However, useful 2D culture conditions do 
not satisfyingly emulate the in vivo scenario, and new 
information on cancer cell behavior could be exposed 
under a more relevant physiological environment [10].
Microfluidic technologies have been proposed as 
improved in vitro tools, once they can be projected 
to display complex structures within dynamic envi-
ronments [11]. A microfluidic device, such as Vena8 
biochip, is able to realize functions that are not eas-
ily imaginable in conventional 2D biological analysis, 
such as highly parallel, sophisticated high-throughput 
analysis and single-cell analysis, in terms of morphol-
ogy, secretome and the influence of growth factors in a 
well-defined manner that could be beneficial in cancer 
research [12,13]. Its microfluidic channels on a microm-
eter and a submicrometer scale are made to mimic 
human capillaries and allow controlling the flow forces, 
the mixture of solutions, and the supply of nutrients and 
biochemical agents in gradients. Moreover, we hypoth-
esized that this model with particular in vivo like fea-
tures, such as the presence of shear stress, flow and con-
finement, will shed light on what happens when NPs are 
injected in vivo and disclose different interactions from 
those observed in traditional 2D in vitro assays. Other 
advantage of microfluidics is the inherent miniaturiza-
tion with a reduction in cell density and amount of 
material needed for an experiment, which can increase 
efficiency when working with primary cells, while test-
ing different concentrations of extracts or drugs can be 
performed simultaneously [14,15]. In fact, the combina-
tion of microfluidics with tissue engineering to study 
cancer has been recently reported with very promising 
results in angiogenesis and metastasis [16,17]). These two 
mechanisms are essential to understand the complex 
development of cancer [18,19], by providing new data on 
crosstalk among several cell types.
The association of NP tracking systems with micro-
fluidics holds great promise as an accurate platform 
for the in vitro validation of new therapies and, con-
sequently, expediting the translation of those therapies 
into the clinic. In fact, a major problem that has been 
hampering this translation is the lack of proper in vitro 
models capable of emulating the in vivo environment, 
including all the barriers naturally present, such as the 
blood flow and the interactions with the endothelium 
and with cells, which are not usually taken into con-
sideration, and the absence of fluorescent-labeled drug 
delivery systems that prevent the monitoring of therapy 
efficiency [6,20,21]. Additionally, little is known about 
NPs’ effect when submitted to a physiologically relevant 
environment similar to the one that cells are surrounded 
of, further highlighting limitations of the conventional 
2D culture conditions. In the work of Fede et al., it 
is possible to observe the effect of directional flow, as 
observed in blood vessels, in the cellular uptake of gold 
NPs, and their noncytotoxicity as compared with cells 
cultured under static conditions [22].
To address the aforementioned problems, we 
hypothesized that the use of labeled NPs together 
with a microfluidic platform is suitable for cancer 
cell and drug delivery system tracking in real time, 
which better mimics the in vivo microenvironment 
than traditional static cultures. This platform works 
as a transitional model for the assessment of dynamic 
NP internalization and cancer cell tracking, which 
will be useful in subsequent studies with 3D mod-
els. The labeled NPs were achieved by grafting the 
fluorescent label probe fluorescein-5(6)-isothiocyanate 
(FITC) to carboxymethylchitosan/poly(amidoamine) 
(CMCht/PAMAM) dendrimer NPs. It is noteworthy 
that dendrimer NPs can be easily labeled with differ-
ent fluorochromes, depending on the need for com-
bining different co-stainings. In this work, surface-
modified dendrimers were used due to its remarkable 
physicochemical and biological properties, and have 
great potential to be used in fundamental cell biol-
ogy [23,24,25]. Moreover, since the biological proper-
ties of poly(amidoamine) (PAMAM) dendrimers can 
be tuned with respect to their terminal functionality, 
it is important to investigate the biocompatibility of 
any new classes of derivatives of PAMAM dendrimers 
 proposed for biological applications.
The modified NPs were characterized with several 
physicochemical techniques, such as dynamic light 
scattering (DLS), proton NMR (H1 NMR), transmis-
sion electron microcopy (TEM), atomic force micros-
copy (AFM) and differential scanning calorimetry 
(DSC). Cytotoxicity was screened using three differ-
ent human cancer cell lines: U87MG (glioblastoma); 
HeLa (cervical cancer) and HCT-116 (colon can-
cer) by means of performing a tetrazolium reduction 
(MTS) assay. Proliferation studies were carried out 
using a DNA quantification assay. Cancer cell lines 
were exposed to different concentrations of CMCht/
PAMAM dendrimer NPs over a period of 3 days in 
conventional 2D standard conditions. After finding 
the highest noncytotoxic concentration, the internal-
ization efficiency was assessed, both qualitatively and 
quantitatively (using fluorescence microscopy and flow 
cytometry, respectively), in static 2D cultures and 
dynamic conditions using Vena8 biochips.
Materials & methods
Synthesis of the CMCht/PAMAM dendrimer NPs
CMCht with a degree of deacetylation of 80% and 
degree of substitution of 47% was synthesized by a 
chemical modification route of chitin (Sigma, Darm-
stadt, Germany) as described by Chen and Park [26].
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Starburst PAMAM carboxylic-acid-terminated den-
drimers, hereafter designated as PAMAM-CT (gen-
eration 1.5, 20% (w/v) methanolic solution) with an 
ethylenediamine core were purchased (Sigma-Aldrich). 
CMCht/PAMAM dendrimer NPs were prepared in 
a step-wise manner as follows: increase the genera-
tion of the PAMAM-CT (G 1.5), obtain a PAMAM 
methyl-ester-terminated dendrimer, react PAMAM and 
CMCht (the reaction occurs by a condensation reaction 
between the methyl ester and amine groups), and con-
vert methyl ester groups that do not react into carboxylic 
groups in the CMCht/PAMAM dendrimer, followed 
by precipitation. First, the increase of the dendrimers’ 
generation was carried out. For that, an appropriate vol-
ume of PAMAM-CT (G 1.5) in methanol was trans-
ferred to a volumetric flask and the solvent evaporated 
off under nitrogen gas, and the traces dried under vac-
uum in order to completely remove the methanol. The 
starting compound was re-dissolved in ultrapure water 
to give a final concentration of 10 mg ml-1 and the pH 
was adjusted to 6.5 with dilute hydrochloric acid solu-
tion (Riedel de-Haen, Schwerte, Germany). 1-Ethyl-
(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC, Fluka, Darmstadt, Germany) was then added 
to the solution at a molar ratio sufficient to modify the 
carboxylate residue of the dendrimers, and the solution 
was kept under agitation for 30 min at room tempera-
ture. Ethylenediamine (Sigma, Germany) was added to 
the solution at a molar ratio equal to that of EDC and 
left to react for at least 4 h. After this period, the excess 
of EDC was removed by dialysis (cellulose tubing, ben-
zoylated for separating compounds with a molecular 
weight of ≤1200, Sigma, Germany). The compound 
was used without purification in the next step. After pre-
paring the PAMAM-amine terminated compound, an 
exhaustive alkylation of the primary amines (Michael 
addition) was performed. An appropriate volume of 
the PAMAM-amine terminated compound was mixed 
with methanol (Sigma, Germany) and methyl methac-
rylate). The solution was kept under agitation in a water 
bath for 24 h at 50°C, to obtain the PAMAM-methyl 
ester. The CMCht in ultrapure water was mixed with 
the PAMAM-methyl ester dendrimer, which was previ-
ously dissolved in a 20/80 water/methanol (v/v) solu-
tion. The final solution was diluted by adding methanol 
and kept under agitation for 72 h. After this period, 
CMCht/PAMAM dendrimers with carboxylic-termi-
nated groups were obtained as described elsewhere [27]. 
CMCht/PAMAM dendrimer NPs were then precipi-
tated after addition of an appropriate volume of saturated 
Na
2
CO
3
 (Aldrich, Germany) solution and cold acetone 
(Pronalab, Tlalnepantla, Portugal). Precipitates were 
collected by filtration and dispersed in ultrapure water 
for dialysis over a period of 48 h. CMCht/PAMAM 
dendrimer NPs were obtained by freezing the solution at 
80°C and freeze-drying (Telstar-Cryodos-80, Terrassa, 
Portugal) up to 7 days to completely remove the solvent. 
It is worth noting that the CMCht/PAMAM dendrimer 
NPs are water  soluble at physiological pH.
Labeling of CMCht/PAMAM dendrimer NPs 
with FITC
The conjugates of CMCht/PAMAM-FITC were 
obtained by covalently bonding the amine group of 
CMCht and the isothiocyanate group of FITC (10 mg 
ml-1 FITC (Sigma, Germany) in anhydrous DMSO 
(Norconcessus, Ermesinde, Portugal) creating a thio-
urea bond. First, a 10 mg ml-1 CMCht/PAMAM 
dendrimer NP solution was prepared in a carbonate–
bicarbonate coupled buffer of pH 9.2. Then, a solu-
tion of FITC/DMSO was added under agitation and 
kept in the dark at 4°C for 8 h. At this moment, the 
FITC-labeled CMCht/PAMAM dendrimer NP solu-
tion was dialyzed against ultrapure water in order to 
remove unlinked FITC for 24 h and filtered (pore size 
<220 nm) in sterile and dark conditions. The final 
product was obtained after freeze-drying.
Characterization of the CMCht/PAMAM 
dendrimer NPs
Transmission electron microscope
The morphology was investigated by TEM (Philips 
CM-12, FEI Company, The Netherlands, equipped 
with a MEGA VIEW-II DOCU camera and Image 
Software Analyzer SIS NT DOCU). For that, the NPs 
were stained with 2% of phosphotungstic acid and 
placed on copper grids for observation.
Atomic force microscopy
The morphology of the NPs was also investigated 
using AFM. First, the freeze-dried CMCht/PAMAM 
dendrimer NPs were dispersed in ultrapure water to 
obtain a solution with final concentration of 1 mg ml-1 
and then one drop was placed over a 9.9 mm mica disc 
(Agar Scientific, Essex, England) and blown dried with 
nitrogen gas for subsequent characterization. Then, the 
samples were analyzed using the Tapping Mode™ with 
a MultiMode AFM connected to a NanoScope III con-
troller, both from Veeco (NY USA), with noncontact 
silicon nanoprobes (ca. 300 kHz) from Nanosensors, 
Switzerland. All images were plane-fitted using the 
third-degree-flatten procedure included in the Nano-
Scope software version 4.43r8. The morphometric 
analysis was performed using the same software.
Dynamic light scattering
ζ potential and particle size of the CMCht/PAMAM 
dendrimer NPs were measured in a particle size ana-
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lyzer (Zetasizer Nano ZS, Malvern Instruments, Mal-
vern, UK). Particle size analyses were performed by 
DLS, in an aqueous solution with low concentration of 
NPs and using disposable sizing cuvettes. Electropho-
retic determinations of ζ potential were investigated 
using the universal ‘dip’ cell pH 7.4 in phosphate-
buffered saline (PBS) solution. ζ potential was also 
 investigated in water.
NMR spectroscopy
In this work, for the determination of CMCht/
PAMAM dendrimer NPs’ structure, H1NMR analy-
ses were used. For this purpose, NPs were dissolved 
in deuterated water (D
2
O). Then, the NMR spectra 
were obtained with a Mercury-400BB operating at a 
frequency of 399.9 MHz at 50°C. The 1D 1H spectra 
were acquired using a 45° pulse, a spectral width of 
6.3 kHz and an acquisition time of 2.001 s.
Differential scanning calorimetry
DSC was performed to study the thermal stability and 
changes in crystallinity over a range of temperatures. 
A known mass of powder was placed in an aluminum 
pan and a lid was crimped onto the pan. The pan was 
then placed in the sample cell of a DSC module. The 
temperature of the DSC module was equilibrated at 
35°C and then increased at a rate of 10°C min-1 under a 
N
2
 gas purge until the material began to degrade. The 
temperatures were obtained for each peak in the result-
ing curve and provided indications of  temperature sta-
bility and phase transitions.
In vitro studies under static conditions
Cell culture
Three cell lines were used: U87MG cells (human glio-
blastoma cell line), HeLa cells (human cervical can-
cer cell line) and HCT-116 cells (human colon cancer 
cell line) were originally obtained from the American 
Collection of Cell Cultures (ATCC, USA). Cells were 
continuously grown in DMEM (Gibco, MD, USA; 
Invitrogen, CA, USA) supplemented with 10% fetal 
bovine serum and 1% penicillin and streptomycin 
under standard conditions (37°C in a humidified 
atmosphere containing 5% CO
2
). Subcultures of cells 
were performed when confluence reached values of 
approximately 90%. Then, cells were plated at an ini-
tial density of 2 × 104 cells well-1 in 24-well plates and 
exposed to three concentrations of CMCht/PAMAM 
dendrimer NPs (0.1, 0.5 and 1 mg ml-1) for short-term 
exposures comprised between 1 and 3 days.
Cell viability
For the studied cell types (HeLa, U87MG and HCT-116), 
cell viability was assessed by the MTS [3-(4,5-dimeth-
ylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sul-
fophenyl)-2H-tetrazolium] test (VWR, Portugal). At 
each time point, cell culture medium was replaced by 
culture medium containing MTS in a 5:1 ratio and 
incubated for 3 h. Then, 100 μl of solution from each 
well was transferred to 96-well plates, and the optical 
density was determined at 490 nm. Cultures that were 
not exposed to the CMCht/PAMAM dendrimer NPs 
were used as controls.
DNA quantification
To assess the effect of CMCht/PAMAM dendrimer 
NPs on cancer cells, the total amount of DNA was 
measured using the fluorimetric double-stranded DNA 
(dsDNA) quantification kit (Quant-iT™ PicoGreen® 
dsDNA Assay Kit, Molecular Probes). HeLa, U87MG 
and HCT-116 cancer cells were washed with sterile 
PBS and were lysed with 1 ml of ultrapure water in 
each well. The cellular suspensions were transferred 
into microtubes and incubated in a water bath at 37°C 
for 1 h, then stored at -80°C for further analysis. DNA 
standards were prepared with concentrations varying 
between 0 and 2 μg ml-1. Next, 28.7 μl of sample or 
standard, 71.3 μl of PicoGreen solution and 100 μl of 
Tris–HCl–EDTA buffer were mixed in each well of 
an opaque 96-well plate (Alfagene, Carcavelos, Portu-
gal) and were incubated in the dark for 10 min. After 
that, fluorescence was measured using an excitation 
wavelength of 485 nm and an emission wavelength 
of 528 nm. A DNA standard curve was prepared with 
concentrations varying between 0 and 2 μg ml-1 and 
sample DNA values were read off from the standard 
graph.
In vitro studies under a microfluidic platform
Vena8 biochips
The Vena8™ biochip from Cellix® (Dublin, Ireland) 
is constitute by eight channels with 120 μm of height, 
800 μm of width and 2.8 cm of length. Each channel 
is connected to two microwells (one in each end) where 
a microfluidic recirculating pump controlled by an 
iPod Touch (Kima™ pump) is connected. The sample 
volume of each channel was 10 μl. The chip was fab-
ricated in optically clear acrylic with a substrate thick-
ness of 500 μm, enabling the observation of cells using 
bright field, phase-contrast imaging and  fluorescence 
microscopy.
Cell culture
A semiautomated microfluidic platform, Vena8 bio-
chip with a glass coverslip (Tebu-Bio, Portugal), was 
used to mimic physiological flow conditions. Each 
biochip channel was coated with fibronectin (Sigma, 
Germany) and then placed in a humidified sterile 
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Petri dish, incubated at 37°C for 1.5 h. After the 
incubation period, 15,000 cells (HeLa, U87MG or 
HCT-116) were gently added into each microchan-
nel and kept in a sterile Petri dish in the incuba-
tor for 2 h to allow cell adhesion. To prevent dry-
ing, after the initial 30 min of incubation, complete 
medium DMEM was added to the channels. After 
3 h, cells were exposed to 0.5 mg ml-1 of CMCht/
PAMAM dendrimer NPs for short-term exposures 
comprised between 1 and 3 days. Medium was added 
 three-times per day.
Cell viability
Cells were seeded at an initial density of 15,000 cells 
channel-1 (day 1 time point) and 10,000 (day 3 time 
point) and exposed to 0.5 mg ml-1 of CMCht/PAMAM 
dendrimer NPs for short-term exposures comprised 
between 1 and 3 days. The effect of CMCht/PAMAM 
NPs on cell viability was tested with medium renewal 
three-times per day. Cells cultured in complete culture 
medium were used as controls.
To test cell viability using the MTS method, cells 
from each channel were detached using Tryple Express 
(Alfagene, Portugal). Cells were aspirated and col-
lected in a 1.5-ml tube. After centrifugation (5 min, 
1500×g r.p.m.) cells were incubated with culture 
medium containing MTS in a 5:1 ratio and analyzed 
as  aforementioned for 2D standard cell cultures.
DNA quantification
To assess the effect of CMCht/PAMAM dendrimer 
NPs on cancer cells in the microfluidic chip, the total 
amount of DNA was measured using Quant-iT™ Pico-
Green® dsDNA Assay Kit. HeLa, U87MG and HCT-
116 cancer cells were plated at a density of 15,000 cells 
microchannel-1 and incubated with CMCht/PAMAM 
dendrimer NPs at a concentration of 0.5 mg ml-1 up to 
1–3 days. Cells cultured in complete culture medium 
were used as controls. After the incubation, cancer cells 
from each channel were washed with sterile PBS and 
detached using Tryple Express Enzyme (Alfagene, Por-
tugal). Cells were aspirated and collected in a 1.5 ml 
tube and lysed with 1 ml of ultrapure water. The cellu-
lar suspensions were incubated in a water bath at 37°C 
for 1 h, then stored at -80°C for further analysis as 
described previously.
Assessment of internalization efficiency in 
2D standard cultures & using a microfluidic 
platform
Fluorescence microscopy
To assess the internalization and possible cell morpho-
logical changes at each time point, a cell suspension 
was prepared and seeded on tissue culture polystyrene 
coverslips (Sarstedt Inc., USA) in 24-well plates (2 × 
104 cells well-1) and cultured with 0.5 mg ml-1 FITC-
labeled CMCht/PAMAM dendrimer NPs, in standard 
culture conditions for 1 and 3 days. Then cells were 
fixed with 4% formalin (Sigma, Germany) and stained 
for F-actin filaments of the cytoskeleton and nuclei 
with Texas Red-X phalloidin (Molecular Probes, Invi-
trogen, USA) and with 4,6-diamidino-2-phenylindole, 
dilactate (DAPI blue, Molecular Probes), respectively, 
following supplier’s protocol. For dynamic cultures, 
cells were cultured as described previously in the 
microfluidic platform and were fixed with 10 μl chan-
nel-1 of 4% formalin (Sigma, Germany) for 10 min. 
Then, 10 μl channel-1 of DAPI and Texas Red-X phal-
loidin were perfused into the microchannels to stain 
the nuclei and the cytoskeleton F-actin filaments, 
respectively. Finally, cells were observed under the 
fluorescence microscope (AxioImager Z1, Zeiss Inc., 
Oberkochen, Germany).
Flow cytometry analysis
To quantify the internalization of FITC-labeled 
CMCht/PAMAM dendrimer NPs, flow cytometry 
analysis was performed. In static conditions, can-
cer cells were cultured in the presence of 0.5 mg ml-1 
FITC-labeled CMCht/PAMAM dendrimer NPs in a 
6-well plate (2 × 105 cells well-1). Cells cultured in com-
plete culture medium were used as controls. Cells were 
released from a substratum and a cell strainer was used 
to avoid cell clusters. Afterward, 0.5 ml of DMEM 
complete medium was added to each well and samples 
transferred to cytometry tubes.
In dynamic conditions, cancer cells were cultured 
in the presence of 0.5 mg ml-1 FITC-labeled CMCht/
PAMAM dendrimer NPs in the microfluidic chips. 
Cells cultured in complete culture medium were used 
as controls. FACS analysis was carried out to perform 
quantitative analysis on the internalization efficiency 
as well as cell viability, as follows: each channel was 
washed with PBS. Then, PBS was aspirated, and cells 
from each channel were detached using 10 μl of Tryple 
Express and collected in an FACS tube. After cen-
trifugation at 1500×g r.p.m. for 5 min, cells were re-
suspended in 800 μl of a 2% fetal bovine serum in 
PBS solution. Afterward, 5 μl of 7-Aminoactinomy-
cin D (7-AAD; Taper group, Portugal) was added to 
each sample for determining the number of dead cells. 
After this step, cells were loaded in FACSCalibur flow 
cytometer (BD Biosciences Immunocytometry Sys-
tems, CA, USA). Calibrate beads three-color kit (BD 
CaliBRITE™ beads, CA, USA) was used to adjust the 
equipment instrument settings before samples are run 
on the flow cytometer. Finally, data were treated using 
the Flowing Software 2.
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Figure 2. Normalization of MTS results by DNA results of HCT-116, HeLa and U87MG human cancer cell lines in 
static conditions in the presence of poly(amidoamine)/carboxymethylchitosan dendrimer nanoparticles. Assays 
were conducted to assess the cytotoxicity effect of nanoparticles on cell viability at concentrations of 0.1, 0.5 and 
1 mg ml-1 at time points of 1 and 3 days. 
*Significant differences when comparing the different concentrations with control (0 mg ml-1) at each time point. 
ΦSignificant differences when comparing controls from day 3 with day 1 to determine cell proliferation).
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Statistical analysis
Statistical evaluation was performed using GraphPad 
Prism 5.0 software version 5.0a. The nonparametric 
Mann–Whitney test was used to compare two groups 
and the Tukey’s test was used to compare results of 
dendrimers’ cytotoxicity after normalization. Statisti-
cal significance was defined as p < 0.05 for a 95% CI. 
All measurements were taken in triplicate and the data 
are shown as mean ± standard deviation.
Results
Characterization of the CMCht/PAMAM 
dendrimer NPs
In order to gain deeper knowledge on the CMCht/
PAMAM dendrimer NPs’ physicochemical properties, 
both TEM and AFM studies were performed. Their 
architecture determined in dry conditions is depicted 
in Figure 1A & B. From Figure 1A, it is clearly visible 
the monodispersed character of these particles, as well 
as the polymer coating around PAMAM’s core and 
a clear dendron-like morphology, which was further 
confirmed by AFM analysis as shown in Figure 1B. In 
fact, it is possible to observe the 3D AFM image of 
the CMCht/PAMAM dendrimer NPs, which notice-
ably shows the consistency of these molecules, in other 
words, nanosphere-like shape. By assessing the particle 
distribution using DLS, it revealed that the CMCht/
PAMAM dendrimer NPs have an average size of 
50 nm (Figure 1C). After the synthesis of the CMCht/
PAMAM dendrimer NPs, three types of particles were 
clearly detected, with sizes approximately 6 ± 1, 54 ± 
7 and 674 ± 462 nm. The first graph corresponds to 
the modified dendrimer NPs with CMCht where two 
peaks are present, corresponding to single and aggre-
gated NPs, respectively. The second graph corresponds 
to the unmodified PAMAM dendrimer of generation 
1.5, also with two visible peaks. These correspond to 
single and aggregated NPs. ζ potential data show that 
NPs dispersed in water at neutral pH present negative 
charge of -34.3 ± 3 (mV).
Figure 1D shows the H1NMR spectrum of the syn-
thesized CMCht/PAMAM dendrimer NPs and its 
comparison with unmodified PAMAM dendrimer 
and biocompatible polymer CMCht, revealing a sin-
glet at 2.49 ppm and multiplets from 3.1 to 3.73 ppm 
and 4.07 ppm associated with the H2 protons, the ring 
methine protons (H3, H4, H5 and H6), and protons 
of –CH
2
COO– groups of the CMCht. Also, peaks 
at 2.49 and 3.46 ppm appear overlapped as a result of 
the resonances of the CH
2
COO and CH
2
 protons of 
both CMCht and PAMAM. The presence of the peak 
at ca. 3 ppm and the absence of a peak at 4.3 ppm 
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Figure 3. Cytotoxicity of poly(amidoamine)/
carboxymethylchitosan over HCT-116, HeLa and 
U87MG human cancer cell lines in static and 
dynamic conditions. Assays were conducted to assess 
cytotoxicity/viability over the cells at a concentration of 
0.5 mg ml-1 at different time points (days 1 and 3) and it 
in static and dynamic conditions. 
*Significant differences when comparing 0.5 mg ml-1 
with control (0 mg ml-1) at each time point. 
ΦSignificant differences when comparing controls from 
day 3 with day 1 to determine cell proliferation).
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can indicate that the substitutions occurred mainly 
on the C2 amino group of CMCht. Finally, DSC 
thermogram analysis to assess thermal stability of the 
modified dendrimer shown in Figure 1E reveals a glass 
transition temperature (Tg) of -13.7°C and a thermal 
 decomposition at 267°C.
Cell viability/proliferation in static conditions
Cell viability and proliferation were determined by 
means of performing MTS and DNA quantification 
assays (Figure 2). The three chosen cancer cell lines 
were exposed to a range of dendrimer concentrations 
over a period of 3 days. Our results indicated no dele-
terious effects on cell viability in static culture condi-
tions, when comparing the tested and control samples 
(p < 0.0001). Therefore, the tested conditions were 
not affected significantly by the presence of CMCht/
PAMAM dendrimer NPs. It is clear that all cancer 
cell lines proliferate in a significant manner from 
day 1 to day 3 in the absence of NPs (controls). As 
depicted in Figure 2, the concentration with less vari-
ability, more consistent results (low standard devia-
tions) and more alike to the control group (no statis-
tically significant differences) was 0.5 mg ml-1. These 
preliminary tests allowed us to screen three types of 
relevant cancer cell lines with a wide range of concen-
trations and choose the most adequate one to proceed 
to comparative studies between static and dynamic 
conditions of culture, in order to validate a model 
for real-time tracking. So, from this point onward, 
all the tests were performed with a dendrimer NP 
 concentration of 0.5 mg ml-1.
Cell viability/proliferation in dynamic 
conditions
Figure 3 shows the results of the two tested groups 
(static and dynamic) at day 1 and day 3, in the absence 
or presence of NPs (0.5 mg ml-1), for easy compari-
son. The shown results represent the normalization 
between the two tests. Regarding the dynamic condi-
tion, HCT-116 cells showed greater sensitivity in the 
presence of NPs, both in day 1 and day 3, which is 
translated into a decrease of viability. U87MG cells, 
by its turn, showed this significant difference between 
the control and NP groups only at day 3. However, for 
HeLa cells, no significant differences were observed in 
dynamic conditions regarding the effect of NPs.
Assessment of NPs cellular uptake in 2D 
standard cultures
Fluorescence microscopy & flow cytometry 
analysis
Figure 4 shows the fluorescence microscopy images 
obtained after culturing the three cancer cell lines 
with 0.5 mg ml-1 of FITC-CMCht/PAMAM for 1 
and 3 days in static conditions. As can be observed, 
all cancer cells were able to internalize the fluorescent 
labeled NPs. NPs are dispersed in the cytoplasm but 
especially around the nucleus (stained with DAPI). 
Also, it is clear that the internalization rate tended to 
increase with time. The microscopic observation of 
cells showed no relevant cell morphological changes, 
which corroborate the lack of cytotoxicity.
Quantitative analysis of NPs’ uptake at the cellular 
level was performed using the flow cytometry analy-
sis. Table 1 shows the percentage of internalization of 
FITC-labeled CMCht/PAMAM dendrimer NPs by 
each cell line under static conditions, as well as the per-
centage of live cells obtained by staining with 7-AAD, 
determined by flow cytometry.
Flow cytometry results of cancer cell lines cultured 
in the presence of FITC-labeled CMCht/PAMAM 
dendrimer NPs showed that HeLa cancer cells contin-
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Figure 4. Fluorescent microscope images of fluorescein-5(6)-isothiocyanate-labeled poly(amidoamine)/
carboxymethylchitosan dendrimer nanoaparticles (green) internalization in cancer cells labeled with 
4,6-diamidino-2-phenylindole, dilactate (nuclei) and phalloidin (F-actin, cytoskeleton) after 1 and 3 days in direct 
contact with dendrimer nanoparticles in static conditions.
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ued to internalize the NPs along time, starting with an 
internalization percentage of 87% by day 1, and increas-
ing to 99% by day 3 (higher fluorescent signals along 
time). By its turn, U87MG and HCT-116 internaliza-
tion rates were constant and reached the maximum 
peak, as almost 100% of cells showed internalized NPs 
only after 24 h. Regarding cell viability in static condi-
tions, it is possible to observe that cells remain viable in 
the presence of dendrimer NPs (percentage of live cells 
on day 1 is very similar to day 3) and no relevant cyto-
toxic effects are noted when  compared with controls 
(see Table 1).
Table 1. FACS data of the percentage of internalization of fluorescein-5(6)-isothiocyanate-labeled 
poly(amidoamine)/carboxymethylchitosan dendrimer nanoparticles and the percentage of live cells 
(stained with 7AAD), from day 1 to day 3 under static conditions.  
Culture conditions Internalization (%) Live cells (%)
Static Day 1 Day 3 Day 1 Day 3 
HeLa (NP) 87 99 96 97
HeLa (control) 0 0 99 99
U87MG (NP) 98 98 97 95
U87MG (control) 0 0 99 99
HCT-116 (NP) 100 99 97 97
HCT-116 (control) 0 0 99 100
NP: Nanoparticle.
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Assessment of internalization efficiency using a 
microfluidic platform
Fluorescence microscopy & flow cytometry analysis
Figure 5 represents a panel of images with results 
obtained after 1 and 3 days of culture in the pres-
ence of FITC-CMCht/PAMAM at a concentration 
of 0.5 mg ml-1, in dynamic culturing conditions. As 
can be observed, all cancer cells were able to internal-
ize the fluorescent-labeled NPs when cultured in the 
 microfluidic system.
Flow cytometry studies on cells cultured in dynamic 
conditions reveal similar results to static conditions 
when it comes to NPs’ internalization performance. 
Cells are able to internalize NPs almost at the maxi-
mum rate by 24 h after the beginning of the experi-
ment (Table 2). Concerning cell viability, it is possible 
to observe differences between the absence and the 
presence of NPs. In fact, all cancer cells show decreased 
viability in the presence of NPs. Special emphasis in 
HCT-116 with a percentage of live cells of 90% when 
compared with the respective control (99%), followed 
by U87MG with 95% against 99% of the control, and 
finally HeLa cells with a percentage of 97% in the pres-
ence of NPs and 100% in the control. It is worth not-
ing that the viability in relation to control was kept 
when analyzing day 3.
Discussion
Although the cancer research field has been evolving 
along the years, there is still missing a proper tool to 
track cells and therapy efficiency in real time, allowing 
the interpretation of their interaction and expediting 
its translation into the clinics. Cell movement, location 
and quantification studies require specialized probes 
that are noncytotoxic and are available in a range of 
fluorescent colors to match instrument lasers and fil-
ters, and to accommodate co-staining with antibodies 
or other cell analysis probes.
In light of this, the main goal of this work was 
aimed at developing a new platform composed of 
fluorescent-labeled NPs associated with a microfluidic 
device, which may be useful for the validation of new 
theranostic approaches. To accomplish this, we inves-
tigated the interactions between a new class of labeled 
NPs, developed previously by our group [28], and sev-
eral cancer cell lines, both in standard 2D static  culture 
systems and in a dynamic microfluidic chip.
The in vitro studies demonstrated that cells remain 
viable in both culturing conditions. However, cell cul-
tures in the dynamic systems displayed higher sensitiv-
ity to NPs, disclosing the real importance of a more 
physiologically relevant model for the development of 
new cancer therapies, otherwise, no differences in cell 
response should be found. Additionally, as the devel-
oped NPs show internalization rates near to 100% (all 
the cells in culture have internalized fluorescent labeled 
NPs) after 24 h in culture, they enable real-time moni-
toring of drug delivery systems efficiency accelerating 
its translation into clinics.
Recently, our group has proposed a strategy to chem-
ically modify PAMAM dendrimer NPs with CMCht 
in order to achieve water solubility and low cytotoxic-
ity, making them ideal for this purpose [28]. The first 
steps were to synthetize and modify the NPs and to 
physicochemically characterize them, prior to their use 
in biological studies. The chosen methods are simple 
and reliable tools to determine chemical composition, 
morphological features and surface chemistry, such as 
TEM, AFM, DLS, H1NMR and DSC methods. In this 
study, the TEM analysis (Figure 1A) clearly revealed a 
dendron-like morphology with a central core and the 
added CMCht polymer coating. These data were fur-
ther confirmed by AFM analysis (Figure 1B) that visibly 
showed the consistency of these molecules’ features, 
in other words, nanosphere-like shape, which is in 
 agreement with previously described results [28,29].
Table 2. FACS data of the percentage of internalization of fluorescein-5(6)-isothiocyanate-labeled 
poly(amidoamine)/carboxymethylchitosan dendrimer nanoparticles and the percentage of live cells 
(stained with 7AAD), from day 1 to day 3 in dynamic conditions.
Culture conditions Internalization (%) Live cells (%)
Dynamic Day 1 Day 3 Day 1 Day 3 
HeLa (NP) 95 100 97 97
HeLa (control) 0 0 100 100
U87MG (NP) 99 99 95 92
U87MG (control) 0 0 99 98
HCT-116 (NP) 100 99 90 90
HCT (control) 0 0 99 99
NP: Nanoparticle.
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Figure 5. Fluorescent microscope images of fluorescein-5(6)-isothiocyanate-labeled poly(amidoamine)/
carboxymethylchitosan dendrimer nanoparticles (green) internalization in cancer cells labeled with 
4,6-diamidino-2-phenylindole, dilactate (nuclei) and phalloidin (F-actin, cytoskeleton) after 24 and 72 h in direct 
contact in dynamic conditions.
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CMCht/PAMAM dendrimer NPs were also ana-
lyzed with DLS. Particle size is one of the most 
important parameters in drug carriers for intracellu-
lar delivery, as well as the surface charge, which was 
also measured. Three sizes of particles were detected, 
approximately 6 ± 1, 54 ± 7 and 674 ± 462 nm 
(Figure 1C). In the first graph, where the analysis of 
CMCht/PAMAM dendrimer is depicted, the first peak 
corresponds to the modified dendrimer and the second 
to the aggregates. Concerning the second graph, the 
first peak matches the size of the isolated unmodi-
fied PAMAM G1.5 dendrimer NPs and the second to 
the size of aggregated NPs. The last group, the aggre-
gated NPs, can be explained by interactions between 
non covalent free carboxyl groups of CMCht and/or 
unmodified PAMAM-carboxyl terminal dendrimer 
and amino groups of other CMCht particles, which 
may promote the formation of NP aggregates [30]. This 
is a property involving not only the surface properties 
of the particles but also their environment, for exam-
ple, pH, ionic strength and even the type of ions in the 
suspension. By its turn, it is expected that CMCht has 
a good pH and ion sensitivity in aqueous solution due 
to abundant –COOH and –NH
2
 groups.
These results corroborate the theory that the nega-
tively charged carboxymethyl groups in the CMCht/
PAMAM dendrimer NPs are mainly distributed at the 
surface of the NPs, working as a water-soluble coating, 
as confirmed by the DLS data.
Regarding the H1NMR analysis, the singlet at 
2.49 ppm and multiplets from 3.1 to 3.73 ppm and 
4.07 ppm are associated with the H2 protons, the ring 
methine protons (H3, H4, H5 and H6) and protons of 
–CH
2
COO- groups of the CMCht, respectively [30,31]. 
Also, the presence of peaks from 1.98 to 3.46 ppm 
is noteworthy because they point the presence of 
PAMAM dendrimer. These have been attributed to 
CH
2
COO, CH
2
CO and CH
2
CN groups. The pres-
ence of the peak at ca. 3 ppm and the absence of a peak 
at 4.3 ppm can indicate that the substitutions occurred 
mainly on the C2 amino group of CMCht, confirming 
the modification of the PAMAM dendrimer.
The DSC studies were performed to assess the ther-
mal stability of PAMAM dendrimers modified with 
10.2217/nnm-2016-0344www.futuremedicine.comfuture science group
Semiautomated microfluidic platform for real-time investigation of NPs’ cellular uptake & cancer cells’ tracking    Research Article
CMCht. The thermal degradation was observed at 
267°C indicating that the developed dendrimers are 
high thermally stable at body temperature. This high 
value could be due to the presence of hydrogen bonds in 
the structure of PAMAM, as observed previously [32]. 
Nevertheless, it is lower than that observed in previ-
ous studies made with other generations of PAMAM 
dendrimers [33]. This variation can be explained by the 
contribution of CMCht polymer. In fact, it was previ-
ously shown that the longer the grafted polymers are, 
the lower the values of thermal degradation obtained, 
and consequently the less stable the dendrimer is [34]. 
Moreover, a thermal glass transition temperature is 
clear at -13.7°C. To the best of our knowledge, this type 
of characterization has never been done in this specific 
type of modified dendrimers and therefore could serve 
as a reference for future works.
Regarding the biological assays, similar to what has 
been done by Oliveira and co-workers for neurons, glial 
cells [29], fibroblasts (L929) and rat bone marrow stromal 
cells [28], the cytotoxic effect of different concentrations 
of CMCht/PAMAM dendrimer NPs on glioblastoma 
cancer cells, colon cancer cells and cervical cancer cells, 
along the time, was the first parameter to be assessed, 
as a bridge to dynamic experiments. This allowed us 
to select the higher noncytotoxic concentration to be 
used in subsequent assays, which was 0.5 mg ml-1. After 
that, standard 2D culture systems in cell culture TCPS 
well-plate (static conditions) and cultures inside a 
microchannel in a microfluidic device (dynamic condi-
tions) were comparatively investigated. The last culture 
system works as a bridge toward more elaborated 3D 
models, as it mimics the natural environment that cells 
and NPs are exposed to, once in systemic circulation in 
vivo [35], regarding confinement, flow and shear stress. 
Figure 2 represents the results of the screening under 
static conditions, which indicates highly metabolically 
active cells. HCT-116, HeLa and U87MG proliferated 
well and were viable either in the controls (absence of 
NPs) or in the presence of NPs at any given concentra-
tion. Statistically, it is possible to observe that increas-
ing concentrations of CMCht/PAMAM (0.1, 0.5 and 
1 mg ml-1) did not affect the viability or proliferation 
of cancer cell lines. This can be explained by the natu-
ral aggressiveness and resistance of cancer cell lines [36] 
when compared with other cell types as showed in the 
work of Oliveira et al. [28,30]. Hence, we decided to use 
the intermediate concentration: 0.5 mg ml-1 as it shows 
no statistical differences when compared with the con-
trols, and because it could potentially increase the num-
ber of NPs inside the cells when compared with the 
 lowest concentration (0.1 mg ml-1).
When static conditions were compared with dynamic 
conditions (Figure 4), in which cells were exposed to 
0.5 mg ml-1 for the same periods of time, HCT-116 
cells showed a clear sensitivity to NPs, especially at day 
3, as well as U87MG cells. None of these phenomena 
were observed in static standard conditions, highlight-
ing the importance of using a system that mimics fea-
tures of the in vivo environment. Therefore, the main 
differences between the two culture conditions rely on 
the fact that NPs show no effect on any of the chosen 
cancer cell lines at any time point in static conditions. 
Nevertheless, when the same cells were cultured in a 
confined and dynamic environment, they showed to 
be more sensitive. Moreover, we observed that their 
growth is much greater in static conditions (statistic 
differences from day 1 to day 3) which can be due to 
the fact that they proliferate freely in traditional 2D 
culture conditions, in contrast to what was observed in 
dynamic conditions due to the limited space available 
within the microchannels of the microfluidic device. 
This is why it is also worth noting the short time expo-
sures (3 days) used in this work instead of the tradi-
tional 14 days’ exposure. In fact, microfluidic devices, 
such as Vena8 chips, are made to speed up and scale 
down experiments [37].
Qualitative images obtained with fluorescence 
microscope revealed that either in static and dynamic 
conditions, HCT-116, U87MG and HeLa cells were 
able to broadly internalize fluorescence labeled NPs at 
a very quick rate after 1 day in culture. The normal 
morphology of the cells (marked by DAPI and phalloi-
din) suggests healthy proliferation and survival under 
both conditions (Figures 4 & 5). It is not clear whether 
the particles are also located inside the nucleus just by 
observing the microscope images. Further experiments 
are required to clarify the fate of these NPs. The same 
effect has been observed earlier by Oliveira et al. [28] in 
L929 and Saos2 cell lines.
These findings were later corroborated by flow 
cytometry, which was used to quantitatively study the 
levels of FITC-labeled CMCht/PAMAM dendrimer 
NPs internalized by cells. Quantitative analysis of NPs’ 
uptake at the cellular level is critical for a realistic eval-
uation of their effects and to compare possible differ-
ent behaviors among different cell culture times. FACS 
analysis was performed to circumvent this limitation 
since each cell line interacts differently with NPs [38].
Results from Table 1 revealed increasing levels of 
fluorescence for HeLa cells from day 1 (87%) to day 3 
(99%), in static conditions. By its turn, U87MG and 
HCT-116 cells’ internalization rates were constant and 
reached the maximum peak, as almost 100% of cells 
showed internalized NPs only after 1 day. A similar 
trend was observed in dynamic conditions (Table 2). 
Although HeLa cells showed slower internalization 
rates, as compared with U87MG and HCT-116 cells, 
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a higher rate of internalization was observed at day 1 
when compared with static conditions (87% in static vs 
95% in dynamic), which could influence, for example, 
the optimization of drug concentration used, showing 
once again the relevance of using a dynamic system 
for validation of new therapies. The fact that HeLa 
cells take more time to internalize NPs in both cul-
ture conditions could be related and possibly explain 
their higher sensitivity. Nevertheless, it is important to 
point out that almost 100% of cells were labeled after 
1 day, indicating that the developed NPs present great 
 potential as the cell-tracking system.
Additionally, we used flow cytometry to measure 
the viability levels of cells in both conditions (static vs 
dynamic) using 7-AAD. 7-AAD appears to be gener-
ally excluded from live cells, creating complexes only 
with free DNA from dead cells, making it an excel-
lent quantitative indicator of cell viability, as it gives 
fluorescent signal for dead cells only. By quantifying 
the percentage of live cells, we observed that there were 
no significant differences between the controls and 
the presence of 0.5 mg ml-1 of NPs in static studies 
(Table 1). On the other hand, when seeded and cul-
tured in the microfluidic chips with dynamic flow, cells 
showed higher sensitivity, displaying higher percent-
ages of dead cells, as depicted in Table 2. It is worth 
noting that the results obtained by flow cytometry 
analysis corroborate the results of MTS/DNA tests.
In brief, these findings suggest that standard 2D 
assays underestimated the effect of CMCht/PAMAM 
dendrimer NPs, while microfluidic chips, which rep-
resent a dynamic setting, unraveled the real cytotoxic-
ity and internalization rates of the labeled NPs [39,40]. 
This could only be possible due to the combination 
of dendrimer NPs with fluorescent dye, which allowed 
real-time monitoring of cells in this new system, envis-
aging the use for new therapies validation in real time. 
Despite the interesting data, we envision performing 
deeper studies to investigate the effect of loading an 
anticancer drug into the NPs on cancer cell lines in the 
proposed microfluidic chip.
Conclusion
This study provided proof-of-concept on the use of a 
platform composed of microfluidic chip together with 
fluorescence-labeled dendrimer NPs for the validation 
of new chemotherapeutic agents. In fact, the results 
show different responses to the presence of 0.5 mg ml-1 
dendrimer NPs when comparing static with dynamic 
conditions, with a tendency toward higher sensitivity 
when subjected to confinement, flow and shear stress 
(dynamic conditions). Moreover, the observed high 
internalization rates of the NPs can be beneficial, mak-
ing them excellent intercellular carrier of anticancer 
drugs. Thus, the microfluidics can enable the develop-
ment of diagnostics platform and personalized thera-
pies, as it opens the possibility to a valuable system to 
test and validate new chemotherapeutic agents in a 
more realistic manner, expediting its translation into 
clinic.
Future perspective
Recent evidence indicates that 3D and flow models 
more closely resemble in vivo function. For example, 
plenteous reports have shown improved functional-
ity with 3D cultures and flow cultures for xenobiotic 
metabolism competence more closely mimicking in 
vivo levels. Therefore, as hypothesized by us, the pro-
posed system has some important features representa-
tive of the in vivo microenvironment, such as confine-
ment, flow and shear stress. This platform, together 
with the efficient ability of cell tracking and drug 
delivery, represents a new step toward dynamic stud-
ies in cancer cells in 3D, namely migration and drug 
testing. Hence, this work further shapes the challenges 
associated with the use of NPs to help deliver drugs 
more specifically and effectively to cancer cells as well 
as to help detect cancer (theranostics). Future NPs and 
microfluidic models can boost drug validation and the 
understanding of tumorigenesis processes, essential 
to move the cancer research field forward in terms of 
 prevention, detection and treatment.
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